BBNX (Beta Bionics) Total Liabilities: $33.2 Mil (As of Mar. 2026)


BBNX Beta Bionics Inc BBNX
10 GF Score
Price $16.18
! 3 Warning Signs
View Full Analysis

What is Beta Bionics Total Liabilities?

Beta Bionics BBNX -4.82% 10 Total Liabilities is $33.2 Mil as of Mar. 2026. GuruFocus rates BBNX with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

Beta Bionics's Total Liabilities for the quarter that ended in Mar. 2026 was $33.2 Mil.

Beta Bionics's quarterly Total Liabilities increased from Sep. 2025 ($35.29 Mil) to Dec. 2025 ($41.13 Mil) but then declined from Dec. 2025 ($41.13 Mil) to Mar. 2026 ($33.17 Mil).

Beta Bionics's annual Total Liabilities increased from Dec. 2023 ($313.15 Mil) to Dec. 2024 ($395.01 Mil) but then declined from Dec. 2024 ($395.01 Mil) to Dec. 2025 ($41.13 Mil).

Beta Bionics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Beta Bionics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Bionics Total Liabilities Chart

Beta Bionics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Liabilities
205.56 313.15 395.01 41.13

Beta Bionics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 24.27 28.34 35.29 41.13 33.17
BBNX
10GF Score
Beta Bionics Inc BBNX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Bionics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Beta Bionics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=30.924+(5.365+1.547
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+3.297+0+0)
=41.1

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=328.743-287.61
=41.1

Beta Bionics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=23.191+(5.073+1.558
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+3.35+0+0)
=33.2

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=304.417-271.245
=33.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $33.2 Mil mean?
Beta Bionics (BBNX) has a Total Liabilities of $33.2 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Beta Bionics and its competitors.
Is Beta Bionics' Total Liabilities too high?
Beta Bionics' current Total Liabilities is $33.2 Mil. Overall, Beta Bionics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Beta Bionics' Total Liabilities compare to CBLL and SIBN?
Beta Bionics' Total Liabilities of $33.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Beta Bionics and its competitors. Beta Bionics's current Total Liabilities is $33.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Bionics stock overvalued right now?
Beta Bionics (BBNX) has a current Total Liabilities of $33.2 Mil. The current Total Liabilities is $33.2 Mil. Beta Bionics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Beta Bionics (BBNX), the current Total Liabilities is $33.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beta Bionics Business Description

Address 11 Hughes, Irvine, CA, USA, 92618
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
10GF Score

Get the complete analysis for BBNX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.18
Price